Argenx SE (ARGX) | Financial Analysis & Statements
Argenx SE Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
1.3B
Gross Profit
1.1B
88.38%
Operating Income
359.6M
27.92%
Net Income
533.0M
41.38%
Balance Sheet Metrics
Total Assets
8.7B
Total Liabilities
1.4B
Shareholders Equity
7.3B
Debt to Equity
0.19
Cash Flow Metrics
Operating Cash Flow
-5.6M
Free Cash Flow
281.7K
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Argenx SE Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.2B | 2.2B | 1.2B | 410.7M | 497.3M |
| Cost of Goods Sold | 450.7M | 227.3M | 117.8M | 29.4M | 0 |
| Gross Profit | 3.7B | 2.0B | 1.1B | 381.3M | 497.3M |
| Gross Margin % | 89.1% | 89.6% | 90.4% | 92.8% | 100.0% |
| Operating Expenses | |||||
| Research & Development | 1.4B | 983.4M | 859.5M | 663.4M | 580.5M |
| Selling, General & Administrative | 1.4B | 1.1B | 709.5M | 469.9M | 305.5M |
| Other Operating Expenses | -83.0M | -58.0M | -42.3M | -30.3M | -31.0M |
| Total Operating Expenses | 2.6B | 2.0B | 1.5B | 1.1B | 855.0M |
| Operating Income | 1.1B | -17.8M | -420.6M | -723.9M | -359.9M |
| Operating Margin % | 25.4% | -0.8% | -34.3% | -176.2% | -72.4% |
| Non-Operating Items | |||||
| Interest Income | 163.1M | 138.7M | 93.0M | 24.7M | 3.5M |
| Interest Expense | 4.1M | 2.5M | 904.0K | 2.2M | 1.1M |
| Other Non-Operating Income | 65.0M | -33.3M | 24.1M | -27.9M | -42.2M |
| Pre-tax Income | 1.3B | 85.2M | -304.5M | -729.3M | -399.7M |
| Income Tax | -13.4M | -747.9M | -9.4M | -19.7M | 8.5M |
| Effective Tax Rate % | -1.1% | -878.0% | 0.0% | 0.0% | 0.0% |
| Net Income | 1.3B | 833.0M | -295.1M | -709.6M | -408.3M |
| Net Margin % | 31.1% | 38.0% | -24.1% | -172.8% | -82.1% |
| Key Metrics | |||||
| EBITDA | 1.2B | 130.8M | -220.8M | -595.5M | -350.5M |
| EPS (Basic) | €21.08 | €13.92 | €-5.16 | €-13.05 | €-7.99 |
| EPS (Diluted) | €19.57 | €12.78 | €-5.16 | €-13.05 | €-7.99 |
| Basic Shares Outstanding | 61295149 | 59855585 | 62004056 | 57012885 | 53547386 |
| Diluted Shares Outstanding | 61295149 | 59855585 | 62004056 | 57012885 | 53547386 |
Income Statement Trend
Argenx SE Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 3.5B | 1.5B | 2.0B | 800.7M | 1.3B |
| Short-term Investments | 948.8M | 1.9B | 1.1B | 1.4B | 1.0B |
| Accounts Receivable | 1.5B | 817.7M | 418.0M | 241.2M | 28.1M |
| Inventory | 473.5M | 407.2M | 310.6M | 228.4M | 109.1M |
| Other Current Assets | - | - | - | -1.0K | - |
| Total Current Assets | 6.9B | 4.9B | 4.1B | 2.8B | 2.5B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 346.0K | 10.1M | 9.2M | 8.5M | 8.3M |
| Goodwill | 272.1M | 181.4M | 125.2M | 174.9M | 171.7M |
| Intangible Assets | 272.1M | 181.4M | 125.2M | 174.9M | 171.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.4B | 1.0B | 176.3M | 128.4M | 66.6M |
| Total Non-Current Assets | 1.8B | 1.3B | 418.7M | 360.1M | 307.3M |
| Total Assets | 8.7B | 6.2B | 4.5B | 3.1B | 2.9B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 554.3M | 482.7M | 245.6M | 188.7M | 208.8M |
| Short-term Debt | 10.8M | 6.5M | 4.6M | 3.4M | 3.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | 1.0K | - |
| Total Current Liabilities | 1.3B | 669.9M | 423.0M | 302.3M | 301.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 36.3M | 32.5M | 15.4M | 9.0M | 8.0M |
| Deferred Tax Liabilities | 0 | 0 | 5.2M | 8.4M | 6.4M |
| Other Non-Current Liabilities | - | - | - | -1.0K | - |
| Total Non-Current Liabilities | 39.4M | 34.3M | 22.0M | 18.3M | 14.8M |
| Total Liabilities | 1.4B | 704.2M | 445.0M | 320.6M | 316.0M |
| Equity | |||||
| Common Stock | 7.4M | 7.2M | 7.1M | 6.6M | 6.2M |
| Retained Earnings | -279.8M | -1.6B | -2.4B | -2.1B | -1.4B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 7.3B | 5.5B | 4.1B | 2.8B | 2.5B |
| Key Metrics | |||||
| Total Debt | 47.2M | 39.1M | 20.0M | 12.4M | 11.5M |
| Working Capital | 5.6B | 4.2B | 3.7B | 2.5B | 2.2B |
Balance Sheet Composition
Argenx SE Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.1B | -21.7M | -425.0M | -720.3M | -348.7M |
| Depreciation & Amortization | 28.1M | 17.5M | 111.3M | 104.3M | 5.9M |
| Stock-Based Compensation | 248.1M | 235.2M | 233.0M | 157.0M | 179.4M |
| Working Capital Changes | -892.8M | -595.2M | -357.2M | -376.1M | -475.8M |
| Operating Cash Flow | 468.8M | -364.4M | -435.9M | -835.0M | -714.4M |
| Investing Activities | |||||
| Capital Expenditures | -6.2M | -1.8M | -812.0K | -837.0K | -3.6M |
| Acquisitions | -6.5M | -7.0M | -13.0M | -2.0M | 0 |
| Investment Purchases | -1.4B | -2.2B | -1.3B | -1.7B | -228.2M |
| Investment Sales | 2.4B | 1.4B | 1.5B | 1.3B | 0 |
| Investing Cash Flow | 926.8M | -762.7M | 258.5M | -371.3M | -231.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -4.1M | -7.6M | -3.8M | -4.2M | -3.9M |
| Financing Cash Flow | -45.4M | -29.5M | 1.2B | 750.6M | 1.1B |
| Free Cash Flow | 573.5M | -151.0M | -464.1M | -966.6M | -728.2M |
| Net Change in Cash | 1.4B | -1.2B | 1.0B | -455.8M | 141.7M |
Cash Flow Trend
Argenx SE Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
39.84
Forward P/E
21.85
Price to Book
6.59
Price to Sales
9.78
PEG Ratio
21.85
Profitability Ratios
Profit Margin
30.50%
Operating Margin
27.44%
Return on Equity
20.15%
Return on Assets
8.86%
Financial Health
Current Ratio
5.23
Debt to Equity
0.64
Beta
-0.09
Per Share Data
EPS (TTM)
€16.72
Book Value per Share
€101.10
Revenue per Share
€69.12
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ARGX | 41.4B | 39.84 | 6.59 | 20.15% | 30.50% | 0.64 |
| Onward Medical N.V | 204.4M | - | 2.98 | -80.85% | 72.51% | 24.70 |
| Hyloris | 152.3M | -23.65 | 5.70 | -21.61% | -71.71% | 6.08 |
| European Medical | 20.7M | 11.14 | 1.72 | 16.43% | 3.46% | 154.89 |
Financial data is updated regularly. All figures are in the company's reporting currency.